ACETAZOLAMIDE
( DrugBank: Acetazolamide / KEGG DRUG: Acetazolamide, Acetazolamide sodium )
6 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis | 1 |
| 90 | Retinitis pigmentosa | 1 |
| 115 | Hereditary periodic paralysis | 1 |
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 155 | Acquired aphasia with convulsive disorder | 1 |
| 225 | Congenital nephrogenic diabetes insipidus | 1 |
| 230 | Alveolar hypoventilation syndrome | 2 |
13. Multiple sclerosis
Clinical trials : 3,685 / Drugs : 1,932 - (DrugBank : 355) / Drug target genes : 263 - Drug target pathways : 237
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
90. Retinitis pigmentosa
Clinical trials : 186 / Drugs : 191 - (DrugBank : 52) / Drug target genes : 43 - Drug target pathways : 87
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
115. Hereditary periodic paralysis
Clinical trials : 2 / Drugs : 3 - (DrugBank : 3) / Drug target genes : 18 - Drug target pathways : 9
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
155. Acquired aphasia with convulsive disorder
Clinical trial : 1 / Drugs : 2 - (DrugBank : 2) / Drug target genes : 29 - Drug target pathways : 14
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
225. Congenital nephrogenic diabetes insipidus
Clinical trials : 17 / Drugs : 40 - (DrugBank : 19) / Drug target genes : 33 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|
230. Alveolar hypoventilation syndrome
Clinical trials : 9 / Drugs : 13 - (DrugBank : 6) / Drug target genes : 17 - Drug target pathways : 27
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|